- AstraZeneca announced positive results in a phase 3 trial of its breast cancer treatment developed with Japan's Daiichi Sankyo.
- The drug treats patients with the most common form of breast cancer .
- The companies said plans for regulatory approval were underway and they were also studying the drug's potential in treating lung cancer.
AstraZeneca (AZN) ADSs rose after announcing that its experimental breast cancer treatment made with Japanese partner Daiichi Sankyo showed high positive results in a phase 3 trial.
AstraZeneca reported that its datopotamab deruxtecan (Dato-DXd) demonstrated “a statistically significant and clinically meaningful improvement in progression-free survival” for patients with inoperable or metastatic hormone receptor-positive breast cancer who received #39;other treatments.
Susan Galbraith, executive vice president of oncology research and development at AstraZeneca, called the findings a “significant development” for people with the most common form of breast cancer whose tumors have become unresponsive to endocrine therapy. .
Companies noted that Plans for global regulatory submissions were underway. They are also investigating the possibility of using Dato-DXd as a treatment for lung cancer.
American Depositary Shares (ADS) AstraZeneca's stock was up 2% in early trading Friday midday ET after the news, but was down 1.4% year to date. br>
Ters? Please email us at email@example.com